GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Net Change in Cash

SEOVF (Sernova Biotherapeutics) Net Change in Cash : $-3.71 Mil (TTM As of Jan. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sernova Biotherapeutics's Net Change in Cash for the three months ended in Jan. 2025 was $-3.34 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jan. 2025 was $-3.71 Mil.

Sernova Biotherapeutics Net Change in Cash Historical Data

The historical data trend for Sernova Biotherapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Net Change in Cash Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.63 19.24 -17.60 3.61 -1.97

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.65 -2.25 1.15 0.72 -3.34

Sernova Biotherapeutics Net Change in Cash Calculation

Sernova Biotherapeutics's Net Change in Cash for the fiscal year that ended in Oct. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-13.736+8.082+3.683+0
=-1.97

Sernova Biotherapeutics's Net Change in Cash for the quarter that ended in Jan. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.355+0+0.015+0
=-3.34

Net Change in Cash for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Net Change in Cash
Comparable Companies
TSXV:MIR XCNQ:ONCO TSXV:COV TSX:ONC TSXV:NRX TSXV:SHRX TSX:MBX XCNQ:DTC XCNQ:GLAB TSX:HBP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
PSH0:Germany SVA:Canada
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Website
https://www.sernova.com
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.